IL136821A0 - Compositions derived from mycobacterium vaccae and methods for their use - Google Patents

Compositions derived from mycobacterium vaccae and methods for their use

Info

Publication number
IL136821A0
IL136821A0 IL13682198A IL13682198A IL136821A0 IL 136821 A0 IL136821 A0 IL 136821A0 IL 13682198 A IL13682198 A IL 13682198A IL 13682198 A IL13682198 A IL 13682198A IL 136821 A0 IL136821 A0 IL 136821A0
Authority
IL
Israel
Prior art keywords
methods
compositions derived
mycobacterium vaccae
vaccae
mycobacterium
Prior art date
Application number
IL13682198A
Other languages
English (en)
Original Assignee
Genesis Res & Dev Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/997,080 external-priority patent/US5968524A/en
Priority claimed from US08/997,362 external-priority patent/US5985287A/en
Priority claimed from US09/095,855 external-priority patent/US6160093A/en
Priority claimed from US09/205,426 external-priority patent/US6406704B1/en
Application filed by Genesis Res & Dev Corp Ltd filed Critical Genesis Res & Dev Corp Ltd
Publication of IL136821A0 publication Critical patent/IL136821A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL13682198A 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use IL136821A0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99662497A 1997-12-23 1997-12-23
US08/997,080 US5968524A (en) 1997-12-23 1997-12-23 Methods and compounds for the treatment of immunologically-mediated psoriasis
US08/997,362 US5985287A (en) 1996-08-29 1997-12-23 Compounds and methods for treatment and diagnosis of mycobacterial infections
US09/095,855 US6160093A (en) 1996-08-29 1998-06-11 Compounds and methods for treatment and diagnosis of mycobacterial infections
US15618198A 1998-09-17 1998-09-17
US09/205,426 US6406704B1 (en) 1996-08-29 1998-12-04 Compounds and methods for treatment and diagnosis of mycobacterial infections
PCT/NZ1998/000189 WO1999032634A2 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use

Publications (1)

Publication Number Publication Date
IL136821A0 true IL136821A0 (en) 2001-06-14

Family

ID=27557521

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13682198A IL136821A0 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use

Country Status (15)

Country Link
EP (1) EP1044273A2 (pt)
JP (1) JP2002514385A (pt)
CN (1) CN1294632A (pt)
AU (1) AU746311B2 (pt)
BR (1) BR9814432A (pt)
CA (1) CA2315539A1 (pt)
HU (1) HUP0100352A2 (pt)
ID (1) ID26327A (pt)
IL (1) IL136821A0 (pt)
MX (1) MXPA00006168A (pt)
NO (1) NO20003261L (pt)
NZ (1) NZ505834A (pt)
PL (1) PL341697A1 (pt)
TR (1) TR200001948T2 (pt)
WO (1) WO1999032634A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
JP4415200B2 (ja) * 1999-01-29 2010-02-17 大塚製薬株式会社 遅発育性抗酸菌ポリペプチド
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6462669B1 (en) 1999-04-06 2002-10-08 E. P . Survivors Llc Replaceable LED modules
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
CA2383496A1 (en) * 1999-07-12 2001-01-18 Genesis Research & Development Corporation Limited Compounds for treatment of infectious and immune system disorders and methods for their use
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
WO2001016327A2 (de) * 1999-08-31 2001-03-08 Michael Niederweis Verfahren zur herstellung eines kanalbildenden proteins
EP2206786A1 (en) * 1999-08-31 2010-07-14 Novozymes A/S Novel proteases and variants thereof
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao Maturity-triggering agent for immature dendritic cells
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US20030104012A1 (en) * 2001-05-11 2003-06-05 Corixa Corporation Vaccines for the treatment of autoimmune disease
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
GB0303507D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
CN116139253B (zh) * 2021-08-10 2025-04-22 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用
CN119162167B (zh) * 2024-11-21 2025-03-11 四川大学华西医院 一种分枝杆菌基因组的提取方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Also Published As

Publication number Publication date
WO1999032634A3 (en) 1999-12-02
CN1294632A (zh) 2001-05-09
JP2002514385A (ja) 2002-05-21
EP1044273A2 (en) 2000-10-18
AU746311B2 (en) 2002-04-18
WO1999032634A2 (en) 1999-07-01
TR200001948T2 (tr) 2001-02-21
NZ505834A (en) 2002-12-20
BR9814432A (pt) 2000-10-10
MXPA00006168A (es) 2005-02-24
AU1893699A (en) 1999-07-12
NO20003261D0 (no) 2000-06-22
ID26327A (id) 2000-12-14
NO20003261L (no) 2000-08-22
CA2315539A1 (en) 1999-07-01
PL341697A1 (en) 2001-04-23
HUP0100352A2 (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
IL136821A0 (en) Compositions derived from mycobacterium vaccae and methods for their use
HUP0001020A3 (en) Stanol composition and the use thereof
GB2319180B (en) Mycobacterial compositions
CY2506B1 (en) Composition
ZA973816B (en) Elastomer compositions and methods.
GB9601398D0 (en) Composition
ZA989399B (en) Method and composition
PL332415A1 (en) Ore cleaning compositions and methods
GB9612595D0 (en) Composition
PL336349A1 (en) Compositions for and methods for treating and diagnosing the mastocarcinoma
EP1056456A4 (en) COMPOSITIONS AND METHODS OF USING R-LANSOPRAZOLE
GB9619074D0 (en) Composition
EP0876157A4 (en) METHODS AND COMPOSITIONS FOR PASSIVE IMMUNOTHERAPY
GB9605247D0 (en) Composition
GB9608485D0 (en) Compositions, processes and uses
AU2664797A (en) Wnt receptor compositions and methods
GB9624501D0 (en) Insecticial compositions and method
GB9600604D0 (en) Composition
ZA9710934B (en) Compositions and methods for administering pneumococal dna
IL120488A0 (en) Modifiers for water-setting inorganic compositions and modified water-setting inorganic compositions
GB2318356B (en) Composition and method
AUPO982097A0 (en) Methods and compositions for use therein
GB9608505D0 (en) Compositions processes and uses
GB9610966D0 (en) Composition
PL330421A1 (en) Antiprespirant composition